Aclaris Therapeutics Inc (NASDAQ: ACRS) on Friday, plunged -5.96% from the previous trading day, before settling in for the closing price of $2.18. Within the past 52 weeks, ACRS’s price has moved between $0.67 and $2.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 74.29%. The company achieved an average annual earnings per share of 49.61%. With a float of $67.57 million, this company’s outstanding shares have now reached $70.89 million.
Considering the fact that the conglomerate employs 91 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 53.53%, operating margin of -150.31%, and the pretax margin is -138.0%.
Aclaris Therapeutics Inc (ACRS) Insider Activity
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Aclaris Therapeutics Inc is 5.41%, while institutional ownership is 70.04%. The most recent insider transaction that took place on Aug 05 ’24, was worth 256,357. In this transaction 10% Owner of this company bought 206,025 shares at a rate of $1.24, taking the stock ownership to the 14,250,000 shares. Before that another transaction happened on Aug 02 ’24, when Company’s 10% Owner bought 167,544 for $1.29, making the entire transaction worth $216,400. This insider now owns 14,043,975 shares in total.
Aclaris Therapeutics Inc (ACRS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 49.61% per share during the next fiscal year.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Aclaris Therapeutics Inc (ACRS) is currently performing well based on its current performance indicators. A quick ratio of 7.03 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.52, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Compared to the last year’s volume of 1.0 million, its volume of 1.14 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 31.34%. Additionally, its Average True Range was 0.20.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 58.64%, which indicates a significant increase from 40.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.41% in the past 14 days, which was higher than the 68.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.49, while its 200-day Moving Average is $1.28. Nevertheless, the first resistance level for the watch stands at $2.22 in the near term. At $2.38, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.48. If the price goes on to break the first support level at $1.96, it is likely to go to the next support level at $1.86. Should the price break the second support level, the third support level stands at $1.70.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
Market capitalization of the company is 137.70 million based on 71,431K outstanding shares. Right now, sales total 31,250 K and income totals -88,480 K. The company made 4,350 K in profit during its latest quarter, and -7,590 K in sales during its previous quarter.
